drugset
drugset / Trial / NCT02581072

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

NCT02581072 ↗

Phase 1 Completed 56 enrolled Novan, Inc. Spaulding Clinical Research LLC · collab
RandomizedCrossoverDouble-blindTreatment

Summary

A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study

Timeline

Start
2015-10
Primary completion
2015-12
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BERDAZIMER SODIUM Small molecule 4 % Topical
Subject BERDAZIMER SODIUM Small molecule 8 % Topical
Subject BERDAZIMER SODIUM Small molecule 12 % Topical

Indications

acne